Abstract
Although there has been unequivocal progress in the development of treatments for multiple sclerosis over the last 20 years, currently licensed treatments have demonstrated convincing effects on disease course only with reference to relapse frequency. This review summarises the progress made, highlights the indications for, and limitations of, current disease-modifying therapies and discusses some interventions currently in development.
| Original language | English |
|---|---|
| Pages (from-to) | 6-13 |
| Number of pages | 8 |
| Journal | Practical Neurology |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2014 |
Keywords
- Clinical Trials as Topic
- Humans
- Multiple Sclerosis, Relapsing-Remitting